Braveheart Bio closed at $21.04 on Nov 2, down 2.19%, 27.9% below its highest close since Sep 11. Volume of 260.1K shares was 0.81× its 20-day average (close to normal).
Split-adjusted performance: -1.1% over one month.
Short interest was 4.9M shares at the Oct 15 settlement, up 18.8% from the prior report (10.9% of float, 11.8 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.1%, revenue growth +6.4%, net margin −36.2%, P/E 15.8×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| BRVEBraveheart Bio | $21.04 | −2.19% | — | — | — | — | $1.89B | |
| TRAXFirst Tracks Biotherapeutics | $45.05 | −0.07% | — | — | — | — | $1.89B | Compare |
| SRPTSarepta Therapeutics, | $18.32 | −1.61% | −16.9% | −34.3% | −1.2% | — | $1.94B | Compare |
| XERSXeris Biopharma Holdings | $10.17 | −5.04% | +60.4% | +28.7% | −33.8% | — | $1.85B | Compare |
| TRVITrevi Therapeutics | $13.63 | +0.52% | −5.2% | — | — | — | $1.94B | Compare |
| PGENPrecigen | $5.14 | −25.94% | +24.2% | +6322.7% | 36.5% | — | $1.84B | Compare |
| SDGRSchrodinger | $26.19 | −3.50% | +103.0% | +7.5% | 10.1% | — | $1.96B | Compare |
| ZBIOZenas BioPharma | $27.62 | −2.71% | +28.1% | — | −11145.6% | — | $1.80B | Compare |
| AGIOAgios Pharmaceuticals | $29.95 | −1.96% | +8.7% | +259.3% | −225.1% | — | $1.79B | Compare |
Braveheart Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics to treat hypertrophic cardiomyopathy (HCM) and other cardiovascular diseases. Its flagship product candidate, BHB-1893, is an oral small-molecule cardiac myosin inhibitor being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM).
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
